About Biokin
Company Founder
Innovative Pharmaceutical Company Synchronizing R&D, Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
SystImmune
Baili-Bio/Baili Pharmaceutical
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Comprehensive Marketing System
Anesthesia
Parenteral Nutrition
Anti-Infectives
Pediatrics
Traditional Chinese Medicines
Investor Relations
Corporate Governance
Announcements & Circulars
Financial Reports
ESG
Listing Documents
Company Presentations
Investor Contacts
Contact Us
EN
中文
繁体
中文
繁体
EN
中文
繁体
中文
繁体
About Biokin
Company Founder
Innovative Pharmaceutical Company Synchronizing R&D, Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
SystImmune
Baili-Bio/Baili Pharmaceutical
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Comprehensive Marketing System
Anesthesia
Parenteral Nutrition
Anti-Infectives
Pediatrics
Traditional Chinese Medicines
Investor Relations
Corporate Governance
Announcements & Circulars
Financial Reports
ESG
Listing Documents
Company Presentations
Investor Contacts
Contact Us
Financial Reports
Home
>
Investor Relations
>
Financial Reports
>
Investor Relations
Corporate Governance
Announcements & Circulars
Financial Reports
ESG
Listing Documents
Company Presentations
Investor Contacts
2024
All
2024
2024 Interim Report
1
